Patent Application
20230304062
The present inventions described herein provide, among other things, cells, cell cultures, polynucleotide and polypeptide constructs, systems and methods for controlling the transcription of one or more polynucleotide sequences of interest. The inventions described herein further provide stable cell lines wherein the transcription of at least one polynucleotide (specifically a polydeoxyribonucleotide) sequence of interest can be tightly controlled in order to control expression of a polypeptide. When an RNA is not transcribed from DNA, a polypeptide cannot be translated from the RNA, which allows for control of protein expression by controlling transcription.
The application contains a Sequence Listing, which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on Oct. 5, 2022, is named “135975-66502.xml” and is 98,737 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety
Various methods for controlled transcription of a polynucleotide sequence of interest in a cell are known to the art and described in U.S. Pat. o. 9,469,856. For example, No et al., Proc. Natl. Acad. Sci. USA 93:3346-3351 (1996) describe a controllable gene expression system utilizing a chimeric transactivator consisting of the ecdysone nuclear receptor fused to the VP16 transactivation domain from herpes simplex virus. Gossen et al., Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992) describe a single system for controlling transcription of a polynucleotide sequence of interest based on a chimeric protein consisting of the tetracycline repressor protein fused with the VP16 transactivation domain. Gossen et al., Science 268: 1766-69 (1995) describes the fusion of a VP16 activation domain with a mutated ‘reverse’ Tet repressor that requires tetracycline for induction. Tetracycline-inducible gene expression is discussed in Ortiz and Johnson, Molec. Biochem. Parasitology 128: 43-40 (2003). Other described single control systems are cited in U.S. Patent No. 9,469,856, including Sadowski et al., Nature 335:563-564 (1988); Brent et al., Cell 40:729-736 (1985); Labow et al., Mol. Cell. Biol. 10:3342-3356 (1990), for example.
Problems resulting from leaky transcription related to the sole reliance on minimal promoters have led to systems using fusions of the steroid-binding domains of the glucocorticoid or estrogen nuclear receptors. See, for example, Mattioni et al., Methods Cell Biol. 43:335-352 (1994); Louvion et al. Gene 131:129-134 (1993); lida et al. J. Virol. 70: 6054-6059 (1996).
Further improvements in regulated expression systems are described and claimed in U.S. Pat. o. 9,469,856. However, ever tighter control of polynucleotide transcription and polypeptide expression is desired.
The present inventions advantageously include and utilize regulatory fusion proteins (RFPs) (which can act as activators or repressors) and repressor proteins (which act as repressors), such as antibiotic repressors, and tandemly arranged operators to control transcription of at least one polynucleotide of interest. Transcription of a single polynucleotide of interest can be controlled according to the inventions or multiple polynucleotides in an operon-like arrangement can be controlled according to the inventions.
As employed herein, a first RFP can bind to a first operator, which can be located 5′ of a promoter and a polynucleotide of interest to be transcribed. A second RFP or a repressor protein can bind to a second operator. The second operator can be located 3′ of a promoter but 5′ of a polynucleotide to be transcribed. In some embodiments, the second operator can be located 3′ of a promoter but 5′ of a polynucleotide to be transcribed and another second operator optionally can be operably linked to a polynucleotide encoding the first RFP or a repressor protein.
The descriptions of aspects and embodiments of the inventions provide methods for controlling the transcription of a polynucleotide of interest in a cell, wherein the method comprises (I) maintaining a cell in a medium without an effective amount of a ligand of both an activator and a repressor, wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding the activator; (C) a second operator; and (D) a polynucleotide encoding the repressor, wherein transcription of the polynucleotide of interest is inhibited in the absence of the ligand of both the activator and the repressor; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the ligand of both the activator and the repressor. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The activator can bind to the first operator in the presence of the ligand to permit transcription of the polynucleotide of interest. The repressor can be a repressor protein, such as an antibiotic repressor, wherein transcription of the polynucleotide of interest is inhibited in the absence of the ligand, and wherein transcription is permitted in the presence of the ligand. The repressor protein can bind to the second operator in the absence of the ligand. The activator can be a regulatory fusion protein (RFP). The ligand can be selected from the group consisting of tetracycline and doxycycline. An activator RFP can be a reverse tetracycline transactivator. A repressor protein can be an antibiotic repressor, such as a tetracycline repressor.
Further provided are methods for controlling the transcription of a polynucleotide of interest in a cell, wherein the method comprises (I) maintaining a cell in a medium without an effective amount of a ligand of an activator (activator ligand) and with an effective amount of ligand of a repressor (repressor ligand), wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding the activator; (C) a second operator; and (D) a polynucleotide encoding the repressor, wherein transcription of the polynucleotide of interest is inhibited in the absence of the activator ligand and the presence of the repressor ligand; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the activator ligand and without an effective amount of the repressor ligand. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The activator can bind to the first operator in the presence of the activator ligand to permit transcription of the polynucleotide of interest. The activator can be a regulatory fusion protein (RFP). The repressor can be a regulatory fusion protein (RFP), wherein transcription of the polynucleotide of interest is inhibited in the presence of the repressor ligand, and transcription is permitted in the absence of the repressor ligand. An activator RFP can be a reverse tetracycline transactivator. The activator ligand can be selected from the group consisting of tetracycline and doxycycline. A repressor RFP can be ArcEr, and the repressor RFP ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen and 4-hydroxytamoxifen (OHT).
There also are provided methods for controlling the transcription of a polynucleotide of interest in cell culture, wherein the methods comprise: I. maintaining at least one cell in a medium with or without an effective amount of a first ligand of a first regulatory fusion protein (RFP) and with an effective amount of a second ligand of a second RFP, wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first RFP, where the first RFP comprises: (1) a transcription activating domain fused to a first DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the operator positioned 5′ when in the presence of the first ligand; (C) a second operator; and (D) a polynucleotide encoding the second RFP that differs from the first RFP, wherein the second RFP comprises: (1) a second DNA binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the second operator in the presence of the second ligand; wherein transcription of the polynucleotide of interest is inhibited in the absence of an effective amount of the first ligand and in the presence of an effective amount of the second ligand; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the first ligand and without an effective amount of the second ligand. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide sequence encoding the protein of interest. Another second operator optionally can be operably linked to the polynucleotide sequence encoding the first RFP. The first RFP as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can comprise an Arc repressor binding domain fused to the estrogen receptor ligand binding domain (ArcEr). The first operator can be a Tet Response Element (TRE). The second operator can be an Arc operator (AO). The cells can further comprise a repressor that is altered by the first ligand. The repressor can be a tet repressor protein (TetR). Additionally, the polynucleotide encoding the first RFP can be operably linked to promoter and optionally a second Arc operator. The promoter can be a CMV promoter, such as CMVmin. ArcEr can control the transcription of the polynucleotide encoding rtTA.
There also are provided methods for controlling the transcription of polynucleotides of interest in cell culture, wherein the methods comprise: (I) maintaining at least one cell in a medium with or without an effective amount of a first ligand of a first regulatory fusion protein (RFP) and with an effective amount of a second ligand of a second RFP, wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by Tet Response Element (TRE) operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first RFP, where the first RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain, wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the operator positioned 5′ when in the presence of the first ligand; (C) an Arc operator operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide encoding the protein of interest; and (D) a polynucleotide encoding the second RFP, wherein the second RFP comprises: (1) an Arc repressor DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the Arc operator in the presence of the second ligand; wherein transcription of the polynucleotide encoding the protein of interest is inhibited in the absence of an effective amount the first ligand and in the presence of an effective amount of the second ligand; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the first ligand and without an effective amount of the second ligand. The first ligand can be selected from the group consisting of tetracycline, doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof. The ligand-binding domain of the second RFP can be the ligand binding domain of a steroid receptor. The first regulatory fusion protein (RFP) as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can be ArcER, which has the Arc repressor binding domain fused to the estrogen receptor ligand binding domain (Arc is a repressor from phage P22). The promoter operably linked to the polynucleotide sequence encoding a polypeptide of interest can be a CMV promoter, such as a CMVmin promoter. A CMV promoter and an Arc operator optionally can be operably linked to the polynucleotide encoding the first RFP. An SV40 E/L promoter, or other constitutive promoter, can be operably linked to the polynucleotide encoding the second RFP.
Moreover, there are provided methods for controlling the transcription of a polynucleotide of interest in a cell, wherein the method comprises (I) maintaining at least one cell in a medium without an effective amount of a ligand of a regulatory fusion protein (RFP) and a repressor protein, wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding the RFP, wherein the RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the ligand is capable of binding to the ligand-binding domain of the RFP, and wherein the DNA binding domain of the RFP is capable of binding to the first operator when in the presence of the ligand; (C) a second operator; and (D) a polynucleotide encoding the repressor protein, wherein the repressor protein can bind to the second operator only in the absence of the ligand, wherein transcription of the polynucleotide is inhibited in the absence of an effective amount of the ligand; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the ligand. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The repressor protein can bind to the second operator in the absence of the ligand to inhibit transcription of the polynucleotide of interest. The RFP can bind to the first operator in the presence of the ligand to permit transcription of the polynucleotide of interest. The ligand can be selected from the group consisting of tetracycline and doxycycline. The activator RFP can be a reverse tetracycline transactivator (rtTA). The repressor protein can be a tetracycline repressor (TetR). The first operator can be a Tet Response Element (TRE). The second operator can be a Tet operator.
Additionally, there are provided methods for controlling the transcription of polynucleotides of interest in cell culture, wherein the methods comprise: (I) maintaining at least one cell in a medium with or without an effective amount of a first ligand of a first regulatory fusion protein (RFP) and with an effective amount of a second ligand of a second RFP, wherein the cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a Tet Response Element (TRE) operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first RFP, wherein the first RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the TRE positioned 5′ when in the presence of the first ligand; (C) a Tet operator operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest; and (D) a polynucleotide encoding the second RFP, wherein the second RFP comprises: (1) an Arc repressor DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the Arc operator in the presence of the second ligand; wherein transcription of the polynucleotide is inhibited in the absence of an effective amount of the first ligand and the presence of an effective amount of the second ligand; and (II) controlling the cell to transcribe the polynucleotide of interest by maintaining the cell in a medium with an effective amount of the first ligand and without an effective amount of the second ligand. The first ligand can be selected from the group consisting of tetracycline, doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof. The ligand-binding domain of the second RFP can be the ligand binding domain of a steroid receptor. The first regulatory fusion protein (RFP) as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can be ArcER. The promoter operably linked to the polynucleotide sequence encoding a polypeptide of interest can be a CMV promoter, such as CMVmin. A CMV promoter and an Arc operator optionally can be operably linked to the polynucleotide encoding the first RFP. An SV40 E/L promoter, or other constitutive promoter, can be operably linked to the polynucleotide encoding the second RFP. The cells can further comprise a polynucleotide encoding a repressor that is altered by the first ligand. The repressor can be TetR.
There also are provided methods for controlling the transcription of a polynucleotide of interest in cell culture, wherein the methods comprise: maintaining at least one cell in a medium with or without an effective amount of a first ligand of a first regulatory fusion protein (RFP) and with an effective amount of a second ligand of a second RFP, wherein the cell comprises (A) a promoter; (B) an Arc operator; and (C) a polynucleotide encoding a reverse tetracycline transactivator fusion protein (rtTA), wherein (A), (B) and (C) are operably linked, and wherein transcription of the rtTA polynucleotide is controlled by a fusion protein comprising an Arc repressor binding domain and an estrogen receptor ligand binding domain (ArcEr); wherein rtTA can control the transcription of a polynucleotide of interest. The promoter can be a CMV promoter, such as CMVmin. The first ligand can be selected from the group consisting of tetracycline and doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof.
The inventions also provide cells capable of controlled transcription of at least one polynucleotide of interest, wherein a cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding an activator; (C) a second operator; and (D) a polynucleotide encoding a repressor, wherein transcription of the polynucleotide of interest is inhibited in the absence of a ligand of both the activator and the repressor, and is permitted in the presence of the ligand of both the activator and the repressor. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The activator can bind to the first operator in the presence of the ligand to permit transcription of the polynucleotide of interest. The repressor can be a repressor protein, wherein transcription of the polynucleotide of interest is inhibited in the absence of the ligand, and wherein transcription is permitted in the presence of the ligand. The repressor protein can bind to the second operator in the absence of the ligand. The activator can be a regulatory fusion protein (RFP). The ligand can be selected from the group consisting of tetracycline and doxycycline. The activator RFP can be a reverse tetracycline transactivator. The repressor protein can be a tetracycline repressor.
Additionally, there are provided cells capable of controlled transcription of at least one polynucleotide of interest, wherein a cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first regulatory fusion protein (RFP), where the first RFP comprises: (1) a transcription activating domain fused to a first DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the operator positioned 5′ when in the presence of the first ligand; (C) a second operator; and (D) a polynucleotide encoding the second RFP that differs from the first RFP, wherein the second RFP comprises: (1) a second DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the second operator in the presence of the second ligand; wherein transcription of the polynucleotide is inhibited in the absence of the first ligand and in the presence of the second ligand and is permitted in the presence of the first ligand and absence of the second ligand. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide sequence encoding the protein of interest. The second operator optionally can be operably linked to the polynucleotide sequence encoding the first RFP. The cells can comprise a polynucleotide that encodes the repressor that is altered by the first ligand. The repressor can be TetR. The polynucleotide (B) encoding the first RFP can be operably linked to promoter and a second Arc operator. The promoter can be a CMV promoter, such as CMVmin. The first RFP as an activator can be a reverse tetracycline transactivator fusion protein (rtTA) and the second RFP as a repressor can be a fusion protein comprising an Arc repressor binding domain and an estrogen receptor ligand binding domain (ArcEr). ArcEr can control the transcription of the polynucleotide encoding rtTA.
Furthermore, there are provided cells capable of controlled transcription of a polynucleotide of interest, wherein a cell comprises (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding an activator; (C) a second operator; and (D) a polynucleotide encoding a repressor; wherein transcription of the polynucleotide of interest is inhibited in the absence of an effective amount if an activator ligand and the presence of an effective amount of a repressor ligand; and permitted in the presence of an effective amount of the activator ligand and the absence of an effective amount of the repressor ligand. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The activator can bind to the first operator in the presence of the activator ligand to permit transcription of the polynucleotide of interest. The activator can be a regulatory fusion protein (RFP). The repressor can be a regulatory fusion protein (RFP), wherein transcription of the polynucleotide of interest is inhibited in the presence of the repressor ligand, and transcription is permitted in the absence of the repressor ligand. The activator RFP can be a reverse tetracycline transactivator. The activator ligand can be selected from the group consisting of tetracycline and doxycycline. The repressor RFP can be ArcEr. The repressor ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen and 4-hydroxytamoxifen (OHT).
There also are provided cells capable of controlled transcription of at least one polynucleotide of interest, wherein a cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by Tet Response Element (TRE) operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first regulatory fusion protein (RFP), where the first RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the operator positioned 5′ when in the presence of the first ligand; (C) an Arc operator operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide encoding the protein of interest; and (D) a polynucleotide encoding the second RFP, wherein the second RFP comprises: (1) an Arc repressor DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the Arc operator in the presence of the second ligand; wherein transcription of the polynucleotide is inhibited in the absence of the first ligand and in the presence of the second ligand and is permitted in the presence of the first ligand and absence of the second ligand. The first ligand can be selected from the group consisting of tetracycline, doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof. The ligand-binding domain of the second RFP can be the ligand binding domain of a steroid receptor. The first regulatory fusion protein (RFP) as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can be ArcER. The promoter operably linked to the polynucleotide sequence encoding a polypeptide of interest can be a CMV promoter, such as a CMVmin promoter. A CMV promoter and an Arc operator optionally can be operably linked to the polynucleotide encoding the first RFP. An SV40 E/L promoter, or other constitutive promoter, can be operably linked to the polynucleotide encoding the second RFP.
In addition, there are provided cells capable of controlled transcription of a polynucleotide of interest, wherein a cell comprises (A) a promoter operably linked to a polynucleotide of interest and controlled by a first operator operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a regulatory fusion protein (RFP), wherein the RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the ligand is capable of binding to the ligand-binding domain of the RFP, and wherein the DNA binding domain of the RFP is capable of binding to the first operator when in the presence of the ligand; (C) a second operator; and (D) a polynucleotide encoding a repressor protein, wherein the repressor protein can bind to the second operator only in the absence of the ligand, wherein transcription of the polynucleotide of interest is inhibited in the absence of an effective amount of the ligand of both the activator and the repressor, and is permitted in the presence of an effective amount of the ligand of both the activator and the repressor. The second operator can be operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest. The repressor protein can bind to the second operator in the absence of the ligand to inhibit transcription of the polynucleotide of interest. The RFP can bind to the first operator in the presence of the ligand to permit transcription of the polynucleotide of interest. The ligand can be selected from the group consisting of tetracycline and doxycycline. The activator RFP can be a reverse tetracycline transactivator (rtTA). The repressor protein can be a tetracycline repressor (TetR). The first operator can be a Tet Response Element (TRE). The second operator can be a Tet operator.
Additionally, there are provided cells capable of controlled transcription of at least one polynucleotide of interest, wherein a cell comprises: (A) a promoter operably linked to a polynucleotide of interest and controlled by a Tet Response Element (TRE) operably linked and positioned 5′ with respect to the promoter; (B) a polynucleotide encoding a first regulatory fusion protein (first RFP), where the first RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the TRE positioned 5′ when in the presence of the first ligand; (C) a Tet operator operably linked and positioned 3′ with respect to the promoter and 5′ with respect to the polynucleotide of interest; and (D) a polynucleotide encoding the second RFP, wherein the second RFP comprises: (1) an Arc repressor DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to the Arc operator in the presence of the second ligand; wherein transcription of the polynucleotide is inhibited in the absence of the first ligand and in the presence of the second ligand and is permitted in the presence of the first ligand and absence of the second ligand. The first ligand can be selected from the group consisting of tetracycline, doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof. The first regulatory fusion protein (RFP) as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can be ArcER. The promoter operably linked to the polynucleotide sequence encoding a polypeptide of interest can be a CMV promoter, such as a CMVmin. A CMV promoter and an Arc operator optionally can be operably linked to the polynucleotide encoding the first RFP. An SV40 E/L promoter, or other constitutive promoter, can be operably linked to the polynucleotide encoding the second RFP. The cell can further comprise a polynucleotide encoding a repressor that is altered by the first ligand. The repressor can be TetR.
Additionally, there are provided cells capable of controlled transcription of at least one polynucleotide of interest when present, wherein a cell comprises: (A) a polynucleotide sequence encoding a first regulatory fusion protein (first RFP), where the first RFP comprises: (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain; wherein the first ligand is capable of binding to the ligand-binding domain of the first RFP, and wherein the DNA binding domain of the first RFP is capable of binding to the operator positioned 5′ when in the presence of the first ligand; (B) a polynucleotide sequence encoding the second regulatory fusion protein (second RFP), wherein the second RFP comprises: (1) a DNA binding domain comprising an Arc repressor DNA-binding domain; and (2) a ligand-binding domain; wherein the second ligand is capable of binding to the ligand-binding domain of the second RFP, and wherein the second RFP is capable of binding to an Arc operator in the presence of the second ligand; (C) one or more insertion sites for a polynucleotide of interest that is operably linked to a promoter and at least one operator. The first ligand can be selected from the group consisting of tetracycline, doxycycline and derivatives thereof. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof. The first regulatory fusion protein (RFP) as an activator can be a reverse tetracycline transactivator (rtTA). The second RFP as a repressor can be ArcER. The promoter operably linked to the polynucleotide sequence encoding a polypeptide of interest can be a CMV promoter, such as a CMVmin promoter. A CMV promoter and an Arc operator optionally can be operably linked to the polynucleotide encoding the first RFP. An SV40 E/L promoter or other constitutive promoter can be operably linked to the polynucleotide encoding the second RFP. A cell can further comprise a polynucleotide encoding a repressor that is altered by the first ligand. The repressor can be TetR.
There also are provided cells capable of controlling the transcription of a polynucleotide of interest, wherein a cell comprises (A) a promoter; (B) an Arc operator; and (C) a polynucleotide encoding a reverse tetracycline transactivator fusion protein (rtTA), wherein (A), (B) and (C) are operably linked, and wherein transcription of the rtTA polynucleotide is controlled by a fusion protein comprising an Arc repressor binding domain and an estrogen receptor ligand binding domain (ArcEr); wherein rtTA can control the transcription of a polynucleotide of interest. The promoter can be a CMV promoter, such as CMVmin. The first ligand can be selected from the group consisting of tetracycline and doxycycline. The second ligand can be selected from the group consisting of estrogen, estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OHT) and derivatives thereof.
There also are provided master cell banks, working cell banks, developmental cell banks, cell cultures, seed cultures, and production cultures comprising cells according to the inventions, as well as bioreactors and fermenters containing cell cultures comprising cells according to the inventions described herein.
Aspects of the embodiments include: maintaining the cells in absence of a first ligand and in the presence of a second ligand, or alternatively in the presence of the first ligand as well. Under these maintenance conditions, the percentage of cells comprising copies of the DNA polynucleotide sequence encoding the polypeptide of interest has reduced less than about 5%. Under the same maintenance conditions, the expression of the polypeptide of interest can be at least 50% less, at least 60% less, at least 70% less, at least 80% less, at least 90% less, or at least 95% less than the expression of the polypeptide in the cells in the presence of the first ligand and the absence of the second ligand after a time period sufficient to allow the second ligand previously-present to clear, usually about 4 to 14 days depending on the second ligand and culture conditions. Under the same maintenance conditions, the number of RNA copies encoding the polypeptide of interest can be at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, or at least 95% less than the number of RNA copies encoding the polypeptide in the cells in the presence of the first ligand and the absence of the second ligand previously-present after a time period sufficient to allow the second ligand to clear, usually about 4 to 14 days depending on the second ligand and culture conditions.
In certain embodiments, the transcription of the polynucleotide sequence encoding the first regulatory fusion protein (first RFP) is inhibited in the presence of the second ligand, such as OHT, and second RFP, such as ArcER.
In certain embodiments, the promoter operably linked to the polynucleotide sequence encoding the protein of interest is a CMV promoter. The promoter may be a CMVmin promoter.
In certain embodiments, the polynucleotide sequence of interest encodes a polypeptide and/or product of interest. The polynucleotide sequence of interest can encode a polypeptide of interest. The polypeptide of interest can be a protein that is toxic or inhibitory to the cell, such as a viral protein.
In certain embodiments, the cells retain the ability to transcribe the polynucleotide of interest in the presence of the first ligand and in the absence of the second ligand, after having been frozen and thawed at least one, at least two, at least three, or at least four times.
In certain embodiments, the cell culture has a cell density of at least 400,000 to one million viable cells per ml while in a repressed state in the presence of the second ligand. While in an induced state in the presence of the first ligand and the absence of the second ligand, the cell culture can have a cell density at least 600,000 to two million viable cells per ml. In further embodiments, the cells are grown in research or production bioreactors having a volume of, for example, at least 2 liters, at least 5 liters, at least 10 liters, 50 liters, at least 75 liters, at least 100 liters, at least 150 liters, at least 200 liters, at least 500 liters, at least 1,000 liters, at least 2,000 liters, at least 5,000 liters, at least 10,000 liters, at least 15,000 liters, at least 20,000 liters or more.
In certain embodiments, the cell is a mammalian cell, such as a primate, canine or rodent cell. In a more specific embodiments, the cell is a CHO cell, such as CHO-K1 cell, a BHK cell, a Human amniotic cell or a HEK293 cell.
In certain embodiments, in the absence of a first ligand and presence of a second ligand, transcription of the polynucleotide sequence encoding the polypeptide of interest is substantially reduced. For example, at least a 10-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand. In certain embodiments, at least a 20-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand. In certain embodiments, at least a 50-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand. In certain embodiments, at least a 100-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand. In certain embodiments, at least a 500-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand.
In certain embodiments, the degree of transcription of the polynucleotide sequence of interest achieved in the presence of the first ligand and the absence of the second ligand may be at least 10-fold greater than in the absence of the first ligand and the presence of the second ligand. In certain embodiments, the degree of transcription of the polynucleotide sequence of interest achieved in the presence of the first ligand and the absence of the second ligand may be at least 20-fold greater than in the absence of the first ligand and the presence of the second ligand. In certain embodiments, the degree of transcription of the polynucleotide sequence of interest achieved in the presence of the first ligand and the absence of the second ligand may be at least 50-fold greater than in the absence of the first ligand and the presence of the second ligand. In certain embodiments, the degree of transcription of the polynucleotide sequence of interest achieved in the presence of the first ligand and the absence of the second ligand may be at least 100-fold greater than in the absence of the first ligand and the presence of the second ligand. In certain embodiments, the degree of transcription of the polynucleotide sequence of interest achieved in the presence of the first ligand and the absence of the second ligand may be at least 500-fold greater than in the absence of the first ligand and the presence of the second ligand.
Other embodiments, aspects, objects and advantages will become apparent from a review of the ensuing detailed description.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this inventions belongs.
The term “about” in the context of numerical values and ranges refers to values or ranges that approximate or are close to the recited values or ranges such that the inventions can perform, such as having a sought rate, amount, density, degree, increase, decrease, extent of transcription or extent of polypeptide expression, concentration, or time, as is apparent from the teachings contained herein. Thus, this term encompasses values beyond those simply resulting from systematic error. For example, “about” can signify values either above or below the stated value in a range of approx. +/- 10% or more or less depending on the ability to perform.
An “effective amount” of a compound refers to the amount of compound needed to cause the intended result, and is typically defined in terms of molar or weight concentration of the compound when present in a medium. Ligands are an example of compounds.
“Capable of binding” refers to the ability of a molecule, such a regulatory fusion protein or portion thereof to bind to another molecule or portion thereof, such ligand binding domains, nucleic acid binding domains, operators, response elements and the like. Typically, binding can permit an action or function or block an action or function.
A “nucleic acid moiety” includes any arrangement of single stranded or double stranded nucleotide sequences. Nucleic acid moieties can include, but are not limited to, polynucleotides, promoters, enhancers, operators, repressors, transcription termination signals, ribosomal entry sites and polyadenylation signals.
A “DNA cassette” or “cassette” is a type of nucleic acid moiety that comprises at least a promoter, at least one open reading frame and optionally a polyadenylation signal. One or more operators also are optional. A DNA cassette thus is a polynucleotide that comprises two or more shorter polynucleotides. A cassette can comprise one or more gene and promoters, enhancers, operators, repressors, transcription termination signals, ribosomal entry sites, introns and polyadenylation signals.
“Operably linked” refers to one or more nucleotide sequences in functional relationships with one or more other nucleotide sequences. Such functional relationships can directly or indirectly control, which refers to inducing, causing, regulating, enhancing, facilitating, permitting, influencing, attenuating, stopping, preventing, repressing and/or blocking one or more actions or activities in accordance with the selected design for a selected purpose. Exemplars include single-stranded or double-stranded nucleic acid moieties, and can comprise two or more nucleotide sequences arranged within a given moiety in such a way that sequence(s) can exert at least one functional effect on other(s). For example, a promoter operably linked to the coding region of a DNA polynucleotide sequence can facilitate transcription of the coding region. Other elements, such as enhancers, operators, repressors, transcription termination signals, ribosomal entry sites and polyadenylation signals also can be operably linked with a polynucleotide of interest to control its transcription. Arrangements and spacing to achieve operable linkages can be ascertained by approaches available to the person skilled in the art, such as screening using western blots and RT-PCR.
“Operator” indicates a DNA sequence that is introduced in or near a polynucleotide sequence in such a way that the polynucleotide sequence may be regulated by the interaction of a molecule capable of binding to the operator and, as a result, prevent or allow transcription of the polynucleotide sequence, as the case may be. One skilled in the art will recognize that the operator must be located sufficiently in proximity to the promoter such that it is capable of controlling transcription by the promoter, which can be considered a type of operable linkage. The operator may be placed either downstream or upstream of the promoter. These include, but are not limited to, the operator region of the Lex A gene of E. coli, which binds the Lex A peptide and the lactose and 45 tryptophan operators, which bind the repressor proteins encoded by the Lad and trpR genes of E. coli. The bacteriophage operators from the lambda Pi and the phage P22 Mnt and Arc. In an alternative embodiment, when the transcription blocking domain of the RFP is a restriction enzyme, the operator is the recognition sequence for that enzyme. Preferred operators are the Tet operator and the Arc operator exemplified herein. Operators can have a native sequence or a mutant sequence (for example, synthetic or semi-synthetic). For example, mutant sequences of the Tet operator are disclosed in Wissmann et al., Nucleic Acids Res. 14: 4253-66 (1986). TRE also functions as an operator and can comprise native operator sequences, mutant operator sequences or combinations of native and mutant operator sequences.
The phrases “percent identity” or “% identical,” in their various grammatical forms, when describing a sequence is meant to include homologous sequences that display tile recited identity along regions of contiguous homology, but the presence of gaps, deletions, or insertions that have no homolog in the compared sequence are not taken into account in calculating percent identity. As used herein, a “percent identity” or “% identical” determination between homologs would not include a comparison of sequences where the homolog has no homologous sequence to compare in an alignment. Thus, “percent identity” and “% identical” do not include penalties for gaps, deletions, and insertions.
A “homologous sequence” in the context of nucleic acid sequences refers to a sequence that is substantially homologous to a reference nucleic acid sequence. In some embodiments, two sequences are considered to be substantially homologous if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% 96%, 97%, 98%, 99% or more of their corresponding nucleotides are identical over a relevant stretch of residues. In some embodiments, the relevant stretch is a complete (i.e., full) sequence.
“Polynucleotide” includes a sequence of nucleotides covalently joined, and includes RNA and DNA. Oligonucleotides are considered shorter polynucleotides. Genes are DNA polynucleotides (polydeoxyribonucleic acid) that ultimately encode polypeptides, which are translated from RNA (polyribonucleic acid) that was typically transcribed from DNA. DNA polynucleotides also can encode RNA polynucleotides that is not translated, but rather function as RNA “products”. The type of polynucleotide (that is, DNA or RNA) is apparent from the context of the usage of the term. A polynucleotide referred to or identified by the polypeptide it encodes sets forth and covers all suitable sequences in accordance with codon degeneracy. Polynucleotides, including those disclosed herein, include percent identity sequences and homologous sequences when indicated.
“Polypeptide” includes a sequence of amino acids covalently joined. Polypeptides include natural, semi-synthetic and synthetic proteins and protein fragments. “Polypeptide” and “protein” can be used interchangeably. Oligopeptides are considered shorter polypeptides.
“Promoter” indicates a DNA sequence that cause transcription of a DNA sequence to which it is operably linked, i.e., linked in such a way as to permit transcription of the nucleotide sequence of interest when the appropriate signals are present and/or repressors are absent. The transcription of a polynucleotide of interest may be placed under control of any promoter or enhancer element known in the art. A eukaryotic promoter can be operably linked to a TATA Box, and most eukaryotic promoters have TATA boxes. The TATA Box is typically located upstream of the transcription start site.
Useful promoters that may be used include, but are not limited to, the SV40 early promoter region, SV40 E/L (early late) promoter, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus, the regulatory sequences of the metallothionein gene, mouse or human cytomegalovirus major immediate early (CMV-MIE) promoter and other CMV promoters, including CMVmin promoters. Plant expression vectors comprising the nopaline synthetase promoter region, the cauliflower mosaic virus 35S RNA promoter, and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I; insulin; immuno globulin; mouse mammary tumor virus; albumin; C.-feto protein; C.1-antitrypsin; 3-globin, and myosin light chain-2. Various forms of the CMV promoter are preferred and the CMVmin promoter is exemplified here.
Minimal promoters, such as CMVmin promoters, tend to be truncated promoters or core promoters and can be used in controlled expression systems. Minimal promoters are more amenable to control. Minimal promoters and development approaches are widely known and disclosed in, for example, Saxena et al., Methods Molec. Biol. 1651:263-73 (2017); Ede et al., ACS Synth Biol. 5:395-404 (2016); Brown et al., Biotech Bioeng. 111:1638-47 (2014); Morita et al., Biotechniques 0:1-5 (2012); Lagrange et al., Genes Dev. 12:34-44 (1998). There are many CMVmin promoters described in the field. It also is possible to use TATA box sequences to perform the role of a promoter.
“Recombinase recognition sites” (RRS), also known as heterospecific recombination sites,” are used in recombinase mediated cassette exchange (RMCE). Cre/Lox, Dre/Rox, Vre/Vlox, SCre/Slox and Flp/Frt are suitable systems, for example . Suitable RRSs for use according to the inventions include Lox P, Lox 66, Lox 71, Lox 511, Lox 2272, Lox 2372, Lox 5171, Lox M2, Lox M3, lox M7 and Lox M11. These sites can be referred to generically as first (1), second (2), third (3), fourth (4), fifth (5), sixth (6), seventh (7), eighth (8), ninth (9), tenth (10), etc., as is apparent from the context of usage.
A “regulatory fusion protein” or “RFP” is a protein that comprises a ligand binding domain and a DNA binding domain that originate from different proteins. Steroid-binding domains of the glucocorticoid or estrogen nuclear receptors can be employed as ligand binding domains. The reverse Tet DNA binding domain (rTet) also is useful as a ligand binding domain, and can bind DNA as well. Exemplary RFPs for use according to the inventions described herein are the reverse tetracycline transactivator (rtTA) and the fusion protein comprising the Arc repressor binding domain (Arc) and the estrogen receptor ligand binding domain (ArcER). Other components for RFPs include the DNA-binding domain of yeast activator GAL4 fused to HSV VP16; the KRAB domain of human Kox1 fused to a prokaryotic Tet repressor (TetR-KRAB); ligand-binding domain of the estrogen receptor (ER) to the carboxyl end of the tTA transactivator (TetR-VP16); and a catalytically inactive formof Cas9 fused to repeats of the minimal activation domain of VP16 (dCas9-VP64). Other fusion proteins include LexA-VP16 and Lacl-VP16. Polynucleotides encoding regulatory fusion proteins (for example, rtTA and ArcEr) can be integrated into the cellular genome as described herein.
A “repressor protein”, also referred to as a “repressor,” is a protein that can bind to DNA in order to repressor transcription. Repressors are of eukaryotic and prokaryotic origin. Prokaryotic repressors are preferred. Examples of repressor families include: TetR, LysR, Lacl, ArsR, IcIR, MerR, AsnC, MarR, DeoR, GntR and Crp families. Repressor proteins in the TetR family include: ArcR, ActII, AmeR, AmrR, ArpR, BpeR, EnvR, EthR, HemR, HydR, IfeR, LanK, LfrR, LmrA, MtrR, Pip, PqrA, QacR, RifQ, RmrR, SimReg2, SmeT, SrpR, TcmR, TetR, TtgR, TrgW, UrdK, VarR YdeS, ArpA, BarA, Aur1B, CalR1, CprB, FarA, JadR*, JadR2, MphB, NonG, PhIF, TyIO, VanT, TarA, TyIP, BM1P1, Bm3R1, ButR, CampR, CamR, DhaR, KstR, LexA-like, AcnR, PaaRR, Psbl, Th1R, UidR, YDH1, BetI, McbR, MphR, PhaD, Q9ZF45, TtK, Yhgd, YixD, CasR, IcaR, LitR, LuxR, LuxT, OpaR, Orf2, SmcR, HapR, Ef0113, HIyllR, BarB, ScbR, MmfR, AmtR, PsrA andYjdC proteins See Ramos et al., Microbiol. Mol. Biol. Rev., 69: 326-56 (2005). Still other repressors include PurR, LacR, MetJ and PadR, Repressor proteins are encoded by genes referred to as “repressor genes” or “repressor protein genes.”
“Reporter proteins” as used herein, refers to any protein capable of generating directly or indirectly a detectable signal. Reporter proteins typically fluoresce, or catalyze a colorimetric or fluorescent reaction, and often are referred to as “fluorescent proteins” or “color proteins.” However, a reporter protein also can be non-enzymatic and non-fluorescent as long as it can be detected by another protein or moiety, such as a cell surface protein detected with a fluorescent ligand. A reporter protein also can be an inactive protein that is made functional through interaction with another protein that is fluorescent or catalyzes a reaction. Accordingly, any suitable reporter protein, as understood by one of skill in the art, could be used. In some aspects, the reporter protein may be selected from fluorescent protein, luciferase, alkaline phosphatase, β-galactosidase, β-lactamase, dihydrofolate reductase, ubiquitin, and variants thereof. Fluorescent proteins are useful for the recognition of gene cassettes that have or have not been successfully inserted and/or replaced, as the case may be. Fluid cytometry and fluorescence-activated cell sorting are suitable for detection. Examples of fluorescent proteins are well-known in the art, including, but not limited to Discosoma coral (DsRed), green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), cyano fluorescent protein (CFP), enhanced cyano fluorescent protein (eCFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP) and far-red fluorescent protein (e.g. mKate, mKate2, mPlum, mRaspberry or E2-crimson. See, for example, U.S. Pat. os. 9,816,110. Reporter proteins are encoded by polynucleotides, and are referred to herein as “reporter genes” or “reporter protein genes.” Reporter genes and proteins can be referred to generically as first (1), second (2), third (3), fourth (4), fifth (5), sixth (6), seventh (7), eighth (8), ninth (9), tenth (10), etc., as is apparent from the context of usage. Reporters can be considered a type of marker. “Color” or “fluorescent,” in their various grammatical forms, also can be used the more specifically refer to a reporter protein or gene.
“Selectable” or “selection” marker proteins include proteins conferring certain traits, including but not limited to drug resistance or other selective advantages. Selection markers can give the cell receiving the selectable marker gene resistance towards a certain toxin, drug, antibiotic or other compound and permit the cell to produce protein and propagate in the presence of the toxin, drug, antibiotic or other compound, and are often referred to as “positive selectable markers.” Suitable examples of antibiotic resistance markers include, but are not limited to, proteins that impart resistance to various antibiotics, such as kanamycin, spectinomycin, neomycin, gentamycin (G418), ampicillin, tetracycline, chloramphenicol, puromycin, hygromycin, zeocin, and/or blasticidin. There are other selectable markers, often referred to as “negative selectable markers,” which cause a cell to stop propagating, stop protein production and/or are lethal to the cell in the presence of the negative selectable marker proteins. Thymidine kinase and certain fusion proteins can serve as negative selectable markers, including but not limited to GyrB-PKR. See White et al., Biotechniques, 50: 303-309 (May 2011). Selectable marker proteins and corresponding genes can be referred to generically as first (1), second (2), third (3), fourth (4), fifth (5), sixth (6), seventh (7), eighth (8), ninth (9), tenth (10), etc., as is apparent from the context of usage.
A “Stable Integration Site” or “SIS” is a region for site-specific integration of DNA polynucleotides, including cassettes that comprise genes and/or other open reading frames, promoters and optionally other elements. Stable Integration Sites can be created according to the methods of the inventions described and depicted herein. Constructs can be inserted into an SIS by a variety of approaches. Multiple Stable Integration Sites can be created and located on different chromosomes, different regions of the same chromosome or different positions in a same region of a chromosome.
A “Tetracycline Response Element” or “TRE” comprises seven copies of the 19 nucleotide TetO spaced apart by spacers comprising 17-18 nucleotides, and are commercially available. TetO sequences can vary and nucleotide substitutions are known. For example, altered sequences based on the Tet operator are disclosed in Wissmann et al., Nucleic Acids Res. 14: 4253-66 (1986). The spacers are not sequence specific. The spacers can be similar, but all should not be identical. A TRE is considered a type of operator as used herein.
All numerical limits and ranges set forth herein include all numbers or values thereabout or there between of the numbers of the range or limit. The ranges and limits described herein expressly denominate and set forth all integers, decimals and fractional values defined and encompassed by the range or limit. The ranges and limits described herein expressly denominate and set forth all integers, decimals and fractional values defined and encompassed by the range or limit. Thus, a recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
The present inventions generally relate to constructs that allow for the tight control of transcription of a polynucleotide sequence in a cell. The present inventions are based on the inquiry and determination that stable cells can be established that transcribe polynucleotide sequences where transcription of the polynucleotide sequence is controlled by an controllable expression system. Cells expressing polynucleotide sequences where transcription of the polynucleotide sequence of interest is controlled by the controllable expression system described herein can be used in a wide variety of applications. The polynucleotide sequence of interest can encode a polypeptide of interest or a product of interest. The controllable expression system described herein is especially useful for controlling the expression of polypeptides of interest and/or products of interest that are toxic or inhibitory to the host cell.
The cells described herein provide the specific advantages that the cells are stable. By “stable” it is meant that the cell can be used to establish a cell line that has regions of interest that are functionally homogenous in culture. The regions of interest would include, for example, polynucleotides of interest and associated promoters, operators, internal ribosome entry sites (IRES), polyadenylation signals and non-translated RNAs, which can be monitored.
Additionally, cells described herein provide the additional advantage that the transcription of polynucleotide encoding the polypeptide of interest is tightly controlled so that the cells are able to survive to a stage permitting large scale expression of the polypeptide of interest. By “tightly controlled” it is meant that in the absence of a first ligand (alternatively in the presence of the first ligand as well) and presence of a second ligand, transcription of the polynucleotide sequence encoding the polypeptide of interest is substantially reduced. Tightest control is achieved in the absence of the first ligand and the presence of the second ligand. For example, in certain embodiments in the repressed state at least a 10-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand in the induced state. In certain embodiments in the repressed state, at least a 20-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand in the induced state. In certain embodiments in the repressed state, at least a 50-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand in the induced state. In certain embodiments in the repressed state, at least a 100-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand in the induced state. In certain embodiments in the repressed state, at least a 500-fold decrease in transcription achieved relative to the level of transcription as seen in the presence of the first ligand and absence of the second ligand in the induced state.
As a corollary to the repressed state, the degree of induction of transcription of the polynucleotide sequence of interest seen in the presence of the first ligand and the absence of the second ligand may be at least 10-fold greater in certain embodiments than in the repressed state. In certain embodiments, the degree of induction of transcription of the polynucleotide sequence of interest in seen in the presence of the first ligand and the absence of the second ligand may be at least 20-fold greater than in the repressed state. In certain embodiments, the degree of induction of transcription of the polynucleotide sequence of interest in seen in the presence of the first ligand and the absence of the second ligand may be at least 50-fold greater than in the repressed state. In certain embodiments, the degree of induction of transcription of the polynucleotide sequence of interest in seen in the presence of the first ligand and the absence of the second ligand may be at least 100-fold greater than in the repressed state. In certain embodiments, the degree of induction of transcription of the polynucleotide sequence of interest in seen in the presence of the first ligand and the absence of the second ligand may be at least 500-fold greater than in the repressed state.
The degree or amount of transcription of the polynucleotide sequence interest may be determined by methods known to those of skill in the art. For example, the level of expression of a polypeptide of interest in a host cell can be determined based on the amount of the corresponding mRNA that is present in the cell. Messenger RNA transcribed from a polynucleotide sequence can be quantified by various methods known by those of skill in the art, including but not limited to, Northern blot hybridization, ribonuclease RNA protection, in situ hybridization to cellular RNA or by PCR.
By way of a further example, the level of expression of a polypeptide of interest in a host cell may also be determined based on the amount of polypeptide of interest encoded by the selected sequence. Polypeptides encoded by a polynucleotide sequence can be quantified by various methods known by those of skill in the art, including but not limited to, ELISA, Western blotting, radioimmunoassays, immunoprecipitation, assay of the biological activity of the polypeptide, immunostaining of the polypeptide followed by FACS analysis or by homogeneous time resolved fluorescence assays (HTRF).
The present inventions relate to a controllable transcription and expression system that may be used to control the transcription of any polynucleotide sequence of interest. The described controllable transcription and expression system comprises at least two controllable operator systems. One of the operator systems can be located 5′ to a promoter that is operably linked to the polynucleotide sequence of interest and the second operator system can be located 3′ of the promoter. The operator systems may comprise operators that are operably linked to a promoter that drives transcription of the polynucleotide sequence of interest. The polynucleotide of interest may encode a polypeptide and/or product (for example, RNA) of interest.
Controllable transcription as described herein allows for transcription of the polynucleotide of interest in the presence of a first ligand and the absence of a second ligand. Briefly, when present, the first ligand binds to a ligand binding site on a first regulatory fusion protein (RFP) which comprises a (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain. Upon binding of the first ligand to the ligand-binding domain of the first RFP, the DNA binding domain of the first RFP binds to a first operator, allowing for transcription from the promoter, but only if transcription is not inhibited by the second operator system. The second operator system is controlled by a second ligand. Briefly, when present, the second ligand binds to a ligand binding site on a second regulatory fusion protein (RFP) which comprises a (1) a transcription blocking domain fused to a DNA binding domain; and (2) a ligand-binding domain. Upon binding of the second ligand to the ligand-binding domain of the second RFP, the DNA binding domain of the second RFP binds to a second operator, blocking transcription from the promoter. Thus, in the presence of the second ligand and absence of the first ligand, transcription is repressed; whereas in the absence of the second ligand and the presence of the first ligand, transcription is permitted.
The first operator system may comprise at least one operator that is operably linked to a promoter that drives transcription of the polynucleotide sequence of interest. The operator of the first operator system may be located 5′ to a promoter that is operably linked to the polynucleotide sequence of interest. Examples of such configurations are shown in
The first operator system also may comprise a regulatory fusion protein (RFP) which comprises a (1) a transcription activating domain fused to a DNA binding domain; and (2) a ligand-binding domain. The first operator system may further comprise a ligand that binds to the ligand-binding domain of the first RFP. Upon binding of the ligand to the ligand-binding domain of the first RFP, the DNA binding domain of the RFP binds to the operator, for example TRE, thereby allowing for transcription from the promoter, but only if transcription is not inhibited by the second operator system as discussed herein. Other system components are known to those of skill in the art, and include for example, the tetracycline on systems (Tet-On), tetracycline on advanced (Tet-On Advanced), tetracycline on 3G systems (Tet-On 3G), cumate-inducible systems, lactose-inducible systems, and variations thereof.
The second operator system can be located 3′ to a promoter that is operably linked to the polynucleotide sequence encoding the polypeptide of interest. Examples of such configurations are shown in
By way of a non-limiting example, suitable controllable operator components for the second operator system are described in U.S. Pat. o. 9,469,856.
Suitable promoters for use with the described system are known and can be determined by those of skill in the art in combinations of choice. In some embodiments, the promoter operably linked to the polynucleotide sequences may be selected from, but is not limited to, the SV40 early promoter region, SV40 E/L promoter, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus, the regulatory sequences of the metallothionein gene, mouse or human cytomegalovirus major immediate early (MIE) promoter; CMVmin promoters, plant expression vectors comprising the nopaline synthetase promoter region, the cauliflower mosaic virus 35S RNA promoter, and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I; insulin; immunoglobulin; mouse mammary tumor virus; albumin; α-fetoprotein; α1-antitrypsin; β-globin; and myosin light chain-2. In some embodiments, the promoter is the human CMV-MIEmin or other CMVmin promoters. Approaches for developing minimal promoters are described in Saxena et al., Methods Molec. Biol. 1651:263-73 (2017); Ede et al., ACS Synth Biol. 5:395-404 (2016); Brown et al., Biotech Bioeng. 111:1638-47 (2014); Morita et al., Biotechniques 0:1-5 (2012); Lagrange et al. Genes Dev. 12:34-44 (1998).
In some embodiments, the polynucleotide sequence of interest encodes a polypeptide of interest. The polynucleotide of interest can be a native gene, including variants thereof, or a synthetic, semi-synthetic or optimized sequence. In other embodiments, the polynucleotide sequence of interest encodes a product (for example, RNA) of interest. More specifically, products of interest may be non-coding RNAs.
“Protein of interest” or “polypeptide of interest” (POI) can have any amino acid sequence, and includes any protein, polypeptide, or peptide, and derivatives, components, domains, chains and fragments thereof. Included are, but not limited to, viral proteins, bacterial proteins, fungal proteins, plant proteins and animal (including human) proteins. Protein types can include, but are not limited to, antibodies, bi-specific antibodies, multi-specific antibodies, antibody chains (including heavy and light), antibody fragments, Fv fragments, Fc fragments, Fc-containing proteins, Fc-fusion proteins, receptor Fc-fusion proteins, receptors, receptor domains, trap and mini-trap proteins, enzymes, factors, repressors, activators, ligands, reporter proteins, selection proteins, protein hormones, protein toxins, structural proteins, storage proteins, transport proteins, neurotransmitters and contractile proteins. Derivatives, components, chains and fragments of the above also are included. The sequences can be natural, semi-synthetic or synthetic. Proteins of interest and polypeptides of interest are encoded by “genes of interest,” which also can be referred to as “polynucleotides of interest.” Where multiple genes (same or different) are integrated, they can be referred to as “first,” “second”, “third,” “fourth,” “fifth,” “sixth,” “seventh,” “eighth,” “ninth,” “tenth,” etc. as is apparent from the context of use.
A polypeptide of interest also can include cytotoxic proteins, such as viral proteins. For example, adenovirus E1A, E1B, E2A and E4 are used to perform functions for production of adeno-associated virus (AAV), but have been reported to be toxic effects in certain cell types. AAV Rep also has been reported to by cytotoxic in certain cell types. Additionally, proteins used in genetic alterations, such as Cre recombinase, Flp recombinase, Zinc finger (ZFN) proteins and dimers, TALEN, bxb 1 integrase, CRISPR associated proteins (Types I-VI; including Cas1, Cas2, Cas3, Cas4, Cas, Cas6, Cas7, Cas8, Cas9, Cas10, Cas11, Cas12 and Cas13) and other nucleases and integrases, can be POIs, and thereby controlled according to the present inventions.
In one aspect, a cell comprising a promoter operably linked to a polynucleotide sequence of interest, wherein the promoter is controlled by at least two operators operably linked to the promoter is provided. The promoter operably linked to the polynucleotide sequence of interest, the operators operably linked to the promoter may be integrated into the cell genome. Transcription of the polynucleotide sequence of interest is controlled by the operators, allowing the transcription of the polynucleotide of interest to be permitted or repressed as preferred.
Cells that are suitable for use with these inventions can be readily selected by those of skill in the art. In some embodiments the cell line is a eukaryotic cell line such as a yeast cell line, insect cell line (for example, Sf9 and Sf21 cells) or a mammalian cell line. Preferred mammalian cells include primate cells (including human), canine cells and rodent cells. Cells can be primary cells or immortalized cells. Suitable cells can be selected from Vero cells, COS cells, HEK293 cells, HeLa cells, CHO cells, BHK cells, Sp2/0 cells, MDCK cells, amniotic cells (including human), embryonic cells, cell lines transfected with viral genes, for example, AD5 E1, including but not limited to an immortalized human retinal cell transfected with an adenovirus gene, for example, a PER.C6 cell, or an NSO cell. In some embodiments, the cell is a Chinese hamster ovary (CHO) cell line. Some examples of CHO cells include, but are not limited to, CHO-ori, CHO-K1, CHO-s, CHO-DHB11, CHO-DXB11, CHO-K1 SV, and mutants/variants thereof. In further preferred embodiments, the CHO cell may be the CHO cell line designated K1. Examples of HEK293 cells include, but are not limited, to HEK293, HEK293A, HEK293E, HEK293F, HEK293FT, HEK293FTM, HEK293H, HEK293MSR, HEK293S, HEK293SG, HEK293SGGD, HEK293T and mutants and variants thereof.
An illustration of the constructs used in creating a cell expressing polynucleotide sequences encoding the crimson fluorescent protein is shown in
In some embodiments, the cell further comprises a polynucleotide sequence encoding one or more regulatory fusion proteins (RFP). The RFP may comprise (a) a transcription activating domain fused to a DNA binding domain and (b) a ligand-binding domain. The ligand is capable of binding to the ligand-binding domain the RFP.
In some embodiments, the cell further comprises a polynucleotide sequence encoding one or more regulatory fusion proteins (RFP), regulatory proteins or repressor proteins. The RFP may comprise (a) a transcription blocking domain fused to a DNA binding domain and (b) a ligand-binding domain. The transcription blocking domain may comprise an Arc repressor DNA-binding domain. A regulatory protein may be TetR. Transcription inhibition of the polynucleotide of interest by binding to the Tet or Arc operator. In some embodiments, the operator is Tet and the transcription blocking domain is a Tet repressor. In other embodiments, the operator is Arc and the transcription blocking domain is an Arc repressor DNA-binding domain.
The cells may further comprise elements that regulate the transcription of the polynucleotide sequence(s) encoding one or more regulatory fusion proteins (RFP). By way of a non-limiting example, transcription of the polynucleotide sequence(s) encoding one or more regulatory fusion proteins (RFP) may be controlled by a Tet-On system, such that the polynucleotide sequence(s) encoding one or more regulatory fusion proteins (RFP) is only transcribed in the presence of Dox. In another embodiment, transcription of rtTA (an RFP) optionally can be under the control of ArcER and AO.
In some instances, the polynucleotide sequence of interest, as well as the operably linked promoter and operators, may be introduced into the cell by transfection of a plasmid containing said polynucleotide sequences and elements. Accordingly, the inventions include the generation of cells as described and cells comprising a plasmid construct as described.
Suitable plasmid constructs can be made by those of skill in the art. Useful regulatory elements, described previously or known in the art, can also be included in the plasmid constructs used to transfect the cells. Some non-limiting examples of useful regulatory elements include, but are not limited to, promoters, enhancers, sequences encoding suitable mRNA ribosomal binding sites, and sequences that control the termination of transcription and translation. Suitable plasmid constructs also may comprise non-transcribed elements such as an origin of replication, other 5′ or 3′ flanking non-transcribed sequences, and 5′ or 3′ non-translated sequences such as splice donor and acceptor sites. One or more markers genes may also be incorporated. Useful markers for use in the present inventions are known and can be readily identified by those of skill in the art.
A plasmid construct encoding a gene of interest may be delivered to the cell using a viral vector or via a non-viral method of transfer.
Non-viral methods of nucleic acid transfer include naked nucleic acid, liposomes, and protein/nucleic acid conjugates. A plasmid construct that is introduced to the cell may be linear or circular, may be single-stranded or doublestranded, and may be DNA, RNA, or any modification or combination thereof.
A plasmid construct may be introduced into the cell by transfection. Those of skill in the art are aware of numerous different transfection protocols, and can select an appropriate system for use in transfecting cells. Generally, transfection methods include, but are not limited to, viral transduction, cationic transfection, liposome transfection, dendrimer transfection, electroporation, heat shock, nucleofection transfection, magnetofection, nanoparticles, biolistic particle delivery (gene gun), and proprietary transfection reagents such as Lipofectamine, Dojindo Hilymax, Fugene, jetPEI, Effectene, or DreamFect.
Upon introduction into the cell, some polynucleotide sequences from the plasmid construct may be integrated into the cell genome, such as a chromosome. In some instances, integration of the polynucleotide sequence into a genome may be achieved with lox sites.
In an embodiment, the promoter operably linked to the polynucleotide sequences of interest, the first operator operably linked to the promoter, and the second operator, are integrated into the cell genome. Other polynucleotides, such as those encoding regulatory fusion proteins (for example, rtTA and ArcEr) and repressor proteins (for example TetR), also can be integrated into the cellular genome as described herein.
In some embodiments, the genomic integration is random. Methods of achieving random genomic integration are known by those of skill in the art, and suitable means can be identified by those of skill. For example, a linearized plasmid with a selectable marker can be used for genomic integration in random locations.
In some embodiments, the genomic integration is site-specific. Site-specific integration refers to the integration at a specific site within a chromosome. Methods of achieving site-specific integration are known by those of skill in the art, and suitable approaches can be identified by those of skill. By way of a non-limiting example, one approach for site-specific integration in CHO cells is described in U.S. Pat. o. 7,771,997 (“Stable Site 1”), which is hereby incorporated by reference, including sequence information. U.S. Patent No. 7,771,997 describes integration sites located at enhanced expression and stability regions. Another suitable integration site is described in U.S. Pat. o. 9,816,110 (“Stable Site 2”), which is hereby incorporated by reference, including sequence information. Regeneron provides a suite of goods and services referred to as EESYR®. CHO cells with integrated sequences in Stable Site 1 and Stable Site 2 are disclosed in US 2019/0233544 A1, which is hereby incorporated by reference, including sequence information. Sequences set forth in these patents and Examples 6 and 7 can be used according to the inventions described and depicted herein. Additionally, an AAVS1-like region and the COSMC locus in hamster cells can be used according to the inventions.
For human cells, such as HEK293 cells, integration can be achieved using the adeno-associated virus integration site 1 (AAVS1) via appropriate plasmids. See Lou et al., Human Gene Therapy Methods, 28: 124-38 (2017); Liu et al., BMC Research Note, 7:626 (2014). AAVS1 is reported to be located in chromosome 19. Additional sites include CCR5 and the Rosa26.
Modification of cellular genomes can be undertaken with known approaches, such as Cre/Lox, Flp/Frt, transcription activator-like effector nuclease (TALEN), a TAL effector domain fusion protein, zinc finger nuclease (ZFN), a ZFN dimer, or a RNA-guided DNA endonuclease system, such as CRISPR/Cas9. See U.S. Patent No. 9,816,110 at cols. 17-18; Sajgo et al., PLoS ONE 9: e91435 (2014); Suzuki et al., Nucl. Acids. Res. 39: e49 (2011). Modification using Bxb1 integrase in human, mouse and rat cells also can be undertaken. Russell et al., Biotechniques 40: 460-64 (2006).
To maximize stability and efficiency and facilitate integration and control of the inventions, Stable Integration Sites (SIS) can be created using Genomic Safe Harbors and the like in a wide variety of cell types and lines according to the teachings of U.S. Serial No. 63/256,675. The descriptions (including examples) and figures providing methods and cells resulting from the methods of U.S. Serial No. 63/256,675 are hereby incorporated by reference.
Accordingly, site-specific and random integration approaches can be employed in in cell. Finally, polynucleotides can exist integrated into non-chromosomal locations as known by the person skilled in the art, such as episomes.
In some embodiments, the cells described herein may comprise a polynucleotide sequence encoding a marker. In an embodiment, the polynucleotide sequence encoding the marker is linked to the polynucleotide sequences encoding the polynucleotide of interest. The polynucleotide sequence encoding the marker may be linked to the polynucleotide sequences of interest such that if the polynucleotide sequence of interest are integrated, the marker polynucleotide sequence is integrated as well. Useful markers for use in the present inventions are known and can be readily identified by those of skill in the art and include, but are not limited to, selectable markers (such as drug resistance markers) and reporter proteins, such as colorimetric/ fluorescent markers.
In another aspect, the inventions provide methods of controlling transcription of a gene of interest in a cell as described. This method has utility in a wide variety of applications, including, by way of not limiting examples, production of proteins/products of interest for therapeutic purposes.
The inventions provide methods of controlling expression of a polypeptide of interest in a cell. In some embodiments, the polypeptide of interest is toxic or inhibitory to the cell, such as a viral gene.
Production of a protein or product of interest starts with a working cell bank (WCB), which typically is stored frozen. The WCB will contain the cells in the absence or presence of the first ligand (for example, dox) and the presence of the second ligand (for example, OHT), as determined by the skilled person. The WCB is thawed and used to create the seed culture (also known as a “seed train”). At the seed culture stage, the cells can be expanded in the absence or presence of the first ligand and in the absence of the second ligand, as determined by the skilled person. As the effectiveness of the inhibition of transcription by the second ligand decreases, typically about 4 to 14 days post seeding (although the time course can be modified by, for example, adding additional second ligand to the cell culture media to delay loss of effectiveness). Following the seed culture stage, production of the protein or product of interest can commence. Non-limiting examples of embodiments are discussed below to further illustrate aspects of the inventions.
Methods and compositions are provided to facilitate the control of transcription of a polynucleotide sequence of interest in a cell culture at various scales (for example, bench top to bioreactor). Further, methods and compositions for achieving a delayed transcription of a polynucleotide of interest in cells in culture also are provided that rely on transitioning from presence of the second ligand to the presence of the first ligand and absence of the second ligand. A delayed transcription includes transcription of the polynucleotide of interest only after or at a point in time after which the cells have grown to a desired density. In general, under some circumstances, it is desirable to allow the cells to reach a desired density, for example, about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% (that is, about 10 to 100%) of maximal achievable density in culture, before a desired amount of transcription of the polynucleotide sequence of interest occurs. In some embodiments, a cell density of about 90 to about 100% is desirable prior to full transcription of the polynucleotide sequence of interest.
In some embodiments, a cell density of at least 400,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least 500,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least 600,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least 700,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least 800,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least 900,000 viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least one million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least two million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least three million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least four million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least five million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least six million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least seven million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least eight million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least nine million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least ten million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least twelve million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. In some embodiments, a cell density of at least fifteen million viable cells per ml is desirable prior to full transcription of the polynucleotide sequence of interest. Typical ranges can be 400,000 to 3 million. Other acceptable ranges include 1 million to 15 million, 2 million to 12 million, 3 million to 10 million, 4 million to 9 million, 5 million to 8 million, and 6 million to 7 million, and any subrange within any of these ranges, as is apparent to the person skilled in the art in view of these teachings.
Delayed induction of transcription can be achieved by any suitable methodology described herein. In various embodiments, delayed induction can be achieved by growing cells to a desired cell density in the presence of an effective amount of the second ligand. In view of the teachings contained herein, the time course of inhibition can be defined by selection of the time course for maintenance of an effective amount of the second ligand in the cell culture. The removal of the second ligand can be achieved by, for example, (i) separating the cells from media containing the second ligand, (ii) diluting the cell culture with media that does not contain the second ligand, and/or (iii) splitting a mixture of the cells and media such that the second ligand is then present at a level below the effective amount (for example, an amount of the second ligand that does not substantially inhibit, or fails to inhibit, transcription of the polynucleotide sequence of interest), sometimes referred to as clearing. In various embodiments, cells are initially grown and/or stored (for example, in a working cell bank (WCB)) with an effective amount of the second ligand.
In various embodiments, cell cultures can be expanded in a medium absent an effective amount of a second ligand. More particularly, during expansion the cell culture has an effective amount of the first ligand and does not have an effective amount of the second ligand for a time period sufficient to allow the second ligand to clear, usually about 4 to 14 days, depending on the second ligand and culture conditions.
In other embodiments, once the desired culture size is reached, and the second ligand no longer effectively inhibits transcription of the cell culture, the polynucleotide of interest can be transcribed in the presence of an effective amount of the first ligand. An effective amount of the first ligand can be added to the cell culture at any appropriate time. For example, the effective amount of the first ligand can be added during seeding. In another example, the effective amount of the first ligand can be added at a later point in time, such as when the second ligand is clearing or already cleared.
One of skill in the art will be able to determine the suitable concentration of the first and second ligands to achieve effective amounts throughout the process. Exemplary concentrations of a ligand may include about 100 nM to about 1,000 nM, about 100 to 900 nM, 100 to 800 nM, about 100 nM to 700 nM, 100 nM to 600 nM, 100 nM to 500 nM, 100 nM to 400 nM, 100 nM to 300 nM, in a specific embodiment about 200 nM to about 500 nM, in another specific embodiment, about 400 nM. Other concentrations can be used as well.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided herein, is intended merely to better illuminate the inventions and does not pose a limitation on the scope of the inventions unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the inventions. As various changes could be made in the above described compositions and methods without departing from the scope of the inventions, it is intended that all matter contained in the above description and in the examples given below, shall be interpreted as illustrative and not in a limiting sense.
The following examples are put forth so as to provide those of ordinary skill in the art how to make and use the cells, methods and compositions described herein, and are not intended to limit the scope of what the inventors regard as their inventions.
CHO-K1 cells were constructed that stably express the crimson florescent protein under the control of both the TRE and ArcO. As shown in
In the induced state, the first ligand, here dox, binds to rtTA and enables it to bind TRE, which is permissive for transcription (trx). When the second ligand is absent, here OHT, ArcER does not inhibit transcription of crimson. It is believed that ArcER is not transported into the nucleus in the absence of an estrogen receptor ligand like OHT or E2. Thus, transcription can proceed where the first ligand is present and the second ligand is absent.
For example, crimson expressing CHO-K1 cells (TRE-AO) can be made by inserting a DNA cassette encoding selectable markers and reporter proteins, as well as polynucleotides encoding rtTA and ArcER into the genome of the cell at the Stable Site 1 according to U.S. Pat.No. 7,771,997. A cassette containing a polynucleotide encoding crimson with a CMVmin promoter can be inserted into the cellular genome at Site 2 according to the teachings of U.S. Pat. No. 9,816,110, for example. The reporter protein was included to confirm integration of the expression cassette into the cellular genome.
Stable integration of the two expression cassettes was confirmed utilizing the included selectable markers.
The ability to tightly control transcription of crimson in the TRE-AO CHO-K1 cells was then tested and compared to a negative control (unmodified cell). As expected, when the ligand for ArcER, here E2, was present and the ligand for rtTA, here Dox, was absent, expression of crimson was highly suppressed. As shown in
Thus, the TRE-AO system provides a means of tightly controlling the transcription of polynucleotides of interest.
Optionally, production of a regulatory fusion protein, such as rtTA, or a repressor protein can be controlled by another regulatory fusion protein and ligand, such as ArcER and AO as depicted in
The use of an RFP, such as ArcER, to control the level of expression of another RFP, such as rtTA, is another optional approach for controlling transcription of a polynucleotide of interest that is under control of that RFP (rtTA in this instance) according the inventions described herein.
CHO- K1 cells were constructed that stably express the crimson fluorescent protein under the control of TRE and a separate TetO. As shown in
When the TetR ligand is present, here dox, it binds to the rtTA, and thereby is permissive for transcription. Additionally, the dox ligand binds to TetR, which lessens the affinity of the Tet repressor for TO and is permissive for transcription. The polynucleotide encoding the repressor protein, such as TetR, can be inserted randomly into the genome or site-specifically into the genome.
As shown in
A HEK293 cell line was constructed with TRE and AO according the teachings contained herein controlling genes for AAV Rep78 and Rep52. See Examples 1 and 4 and
In a repressed state, rtTA is without its ligand (for example, dox) and ArcER is in the presence of its ligand (for example, OHT). See
In this example, the HEK293 cells were transformed with Rep78 and Rep 52, and both genes were under control of the TRE-AO system. The ligands employed were dox and E2 (instead of OHT).
Exemplary sequences are provided below, and other sequences (including homologs and variants) are available to the person skill in the art.
(SEQ ID NO: 1)
(SEQ ID NO: 2)
(SEQ ID NO: 3)
(SEQ ID NO: 4)
(SEQ ID NO: 5)
(SEQ ID NO: 6)
(SEQ ID NO: 7)
(SEQ ID NO: 8)
(SEQ ID NO: 9)
(SEQ ID NO: 10)
211> 6473
<212> DNA
<213> Cricetulus griseus
<400> 1 (SEQ ID NO: 11)
<211> 7045
<212> DNA
<213> Cricetulus griseus
<400> 2 (SEQ ID NO: 12)
<211> 6473
<212> DNA
<213> Cricetulus griseus
<400> 3 (SEQ ID NO: 13)
<211> 7045
<212> DNA
<213> Cricetulus griseus
<400> 4 (SEQ ID NO: 14)
<211> 13515
<212> DNA
<213> Cricetulus griseus
<400> 5 (SEQ ID NO: 15)
<211> 14553
<212> DNA
<213> Mus musculus
<400> 6 (SEQ ID NO: 16)
<211> 4001
<212> DNA
<213> Cricetulus griseus
<400> 1 (SEQ ID NO: 17)
<211> 14931
<212> DNA
<213> Cricetulus griseus
<220>
<221> misc feature
<222> (2176)..(2239)
<223> n is a, c, g, t or nucleotide is missing
<400> 4
It is to be understood that the description, specific examples and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present inventions. Various changes and modifications within the present inventions, including combining embodiments in whole and in part, will become apparent to the skilled artisan from the discussion, disclosure and data contained herein, and thus are considered part of the inventions.
The present inventions may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the inventions.
This Application claims priority to U.S. Application Serial No. 63/256,831, filed Oct. 18, 2021, which is hereby incorporated by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 63256831 | Oct 2021 | US |
